Immune boosters join chemo in fight against ovarian cancer
NCT ID NCT03245892
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This early-phase study looked at adding the immunotherapy drugs nivolumab (with or without ipilimumab) to standard chemotherapy for people with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The main goal was to see if the combination was safe and what side effects occurred. 27 participants received the treatment before and after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.